# Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)

> **NCT02972034** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 111 (actual)

## Conditions studied

- Neoplasms
- Colorectal Cancer

## Interventions

- **DRUG:** MK-8353
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02972034
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-13
- **Primary completion:** 2022-12-02
- **Final completion:** 2022-12-02
- **Target enrollment:** 111 (ACTUAL)
- **Why stopped:** business reasons.
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02972034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02972034, "Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02972034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*